Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMBGZI3)

Drug Name
Chlorpromazine Drug Info
Synonyms
Aminasine; Aminazin; Aminazine; Ampliactil; Amplicitil; Amplictil; BC 135; Chlor-PZ; Chlor-Promanyl; Chlordelazine; Chlorderazin; Chloropromazine; Chlorpromados; Chlorpromanyl (discontinued); Chlorpromazin; Chlorpromazine (USP/INN); Chlorpromazine Tannate; Chlorpromazine [USAN:INN:BAN]; Chlorpromazinum; Chlorpromazinum [INN-Latin]; Clorpromazina; Clorpromazina [INN-Spanish]; Clorpromazina [Italian]; Contomin; Cromedazine; Elmarin; Esmind; Fenactil; Fenaktyl; Fraction AB; HL 5746; JHICC02042; Largactil; Largactil (TN); Largactil Liquid; Largactil Oral Drops; Largactilothiazine; Largactyl; Megaphen; Novo-Chlorpromazine; Novomazina; Phenactyl; Phenathyl; Phenothiazine hydrochloride; Plegomasine; Plegomazin; Prazilpromactil; Proma; Promactil; Promazil; Propaphen; Propaphenin; Prozil; Psychozine; SKF 2601-A; SKF 2601A; SKF-2601; Sanopron; Thorazine; Thorazine (TN); Thorazine Spansule; Thorazine Suppositories; Thorazine hydrochloride; Torazina; Wintermin; Z80
Therapeutic ClassAntipsychotic Agents
Cross-matching ID
PubChem CID
2726
ChEBI ID
CHEMBL71
CAS Number
CAS 34468-21-8
TTD Drug ID
D01ZII
VARIDT Drug ID
DR00502
INTEDE Drug ID
DR0308
ACDINA Drug ID
D00124

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Mineral absorption 2.13 0.00e+0 48/60 (80%) MT1H;MT1E;MT1F;...
Drug metabolism -1.66 4.32e-2 78/151 (51.66%) DPYS;GSTM2;UMPS;...
Spinocerebellar ataxia -1.67 4.43e-2 128/143 (89.51%) SP1;PSMD13;PSMD11;...
Insulin secretion -1.71 2.84e-2 75/86 (87.21%) RAB3A;RAPGEF4;ATP1B2;...
Prion disease -1.73 2.26e-2 209/273 (76.56%) PRKACB;PSMB2;COX7C;...
Retrograde endocannabinoid signaling -1.76 2.09e-2 118/148 (79.73%) KCNJ3;CACNA1A;NDUFC1;...
Pyruvate metabolism -1.76 2.07e-2 41/47 (87.23%) MDH2;ADH6;ADH1A;...
ECM-receptor interaction -1.79 1.39e-2 80/88 (90.91%) COL4A1;DMP1;LAMA5;...
Non-alcoholic fatty liver disease -1.80 1.31e-2 126/155 (81.29%) NDUFA2;ITCH;PRKAG2;...
Hypertrophic cardiomyopathy -1.82 1.21e-2 81/90 (90%) TGFB1;PRKAA1;ITGA1;...
Huntington disease -1.82 1.21e-2 233/306 (76.14%) ITPR1;BDNF;NDUFA10;...
Pyrimidine metabolism -1.83 1.34e-2 40/56 (71.43%) CMPK1;CTPS1;NT5C;...
Citrate cycle (TCA cycle) -1.85 1.06e-2 30/30 (100%) MDH2;IDH3A;SDHA;...
Cardiac muscle contraction -1.87 1.03e-2 64/87 (73.56%) ATP1B2;SLC9A7;ATP2A1;...
Dilated cardiomyopathy -1.89 1.01e-2 86/96 (89.58%) TGFB1;ITGA1;MYH7;...
Thyroid hormone synthesis -1.91 7.24e-3 66/75 (88%) ATP1B2;PRKCB;TG;...
Ribosome -1.94 3.02e-3 113/158 (71.52%) MRPL11;RPS19;RPL35A;...
Oxidative phosphorylation -2.10 0.00e+0 93/133 (69.92%) ATP4A;NDUFC1;ATP6AP1;...
Parkinson disease -2.12 0.00e+0 176/249 (70.68%) PSMB1;TXN;ITPR1;...
Diabetic cardiomyopathy -2.13 0.00e+0 162/203 (79.8%) NDUFA10;ATP5PB;COX8A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 10uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H